Clinical symptoms of COVID-19 among tobacco users in Moradabad city, India: A retrospective observational study

Document Type : Original Article

Authors

1 Kothiwal Dental College & Research Centre, Moradabad, India

2 National Tobacco Control Program, Moradabad, India

3 Maulana Azad Medical College, New Delhi, India

Abstract

Background: Tobacco is one of the leading risk factors for many respiratory infections and is linked to the clinical severity of the disease. COVID-19 primarily infects the lungs and causes severe pneumonia-like illness. Tobacco consumption may thus, increase the risk for developing COVID-19. However, this study was planned to assess the tobacco consumption among COVID-19 patients and determine the relationship between SARS CoV-2 and tobacco use among COVID-19 patients.
Methods: Lists of laboratory-confirmed COVID-19 positive patients aged 18-70 years were obtained from District Government Hospital on November 2020 and were interviewed telephonically after taking informed consent. A total of 470 patients under home isolation for the past one month after getting diagnosed with SARS CoV-2 were recruited in this study. Data was entered in MS Excel 2019 (Microsoft Corp.) and analysis was done using SPSS 25 (IBM Inc.). Chi-square and Fisher’s exact test were used and significance level was set 0.05 with 95% confidence interval.
Results: In the present study, the mean (standard deviation) age of participants was 37.8 (12.1) years. Among the COVID-19 patients, 21% of participants were tobacco users. Clinical symptoms such as fever, severe acute respiratory illness (SARI), acute respiratory illness (ARI), loss of taste/smell, and other symptoms such as body-ache, myalgia, nasal secretion and flue like symptoms were presented; of which most common symptoms were fever (26.8%) followed by SARI or ARI (11.5%) and significantly presented more among tobacco users (66.3%) than non-tobacco users (55.6%) (P = 0.036). Nonetheless smokers, these symptoms also affected significantly SLT users (64.8%) (P = 0.029) and dual tobacco users (100%) (P = 0.010).
Conclusion: Tobacco use may worsen COVID-19 disease symptoms among COVID-19 patients.

Keywords

Main Subjects

References

  1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-33. doi: 10.1056/NEJMoa2001017.
  2. Coronavirus Disease 2019 (COVID-19) Situation Report -33. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200222-sitrep-33-covid-19.pdf?sfvrsn = c9585c8f_4. Accessed February 22, 2020.
  3. MoHFW website. New Delhi: Ministry of Health & Family Welfare. Available from: https://www.mohfw.gov.in/.
  4. Pal M, Berhanu G, Desalegn C, Kandi V. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): an update. Cureus. 2020;12(3):e7423. doi: 10.7759/cureus.7423.
  5. Petrosillo N, Viceconte G, Ergonul O, Ippolito G, Petersen E. COVID-19, SARS and MERS: are they closely related? Clin Microbiol Infect. 2020;26(6):729-34. doi: 10.1016/j.cmi.2020.03.026.
  6. Centers for Disease Control and Prevention (CDC). COVID-19: SARS-CoV-2 Variant Classifications and Definitions. Atlanta, GA: US Department of Health and Human Services, CDC; 2021. Available from: https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html.
  7. Alla F, Berlin I, Nguyen-Thanh V, Guignard R, Pasquereau A, Quelet S, et al. Tobacco and COVID-19: a crisis within a crisis? Can J Public Health. 2020;111(6):995-9. doi: 10.17269/s41997-020-00427-x.
  8. Volkow ND. Collision of the COVID-19 and addiction epidemics. Ann Intern Med. 2020;173(1):61-2. doi: 10.7326/m20-1212.
  9. Cai G, Bossé Y, Xiao F, Kheradmand F, Amos CI. Tobacco smoking increases the lung gene expression of ACE2, the receptor of SARS-CoV-2. Am J Respir Crit Care Med.2020;201(12):1557-9. doi: 10.1164/rccm.202003-0693LE.
  10. Transmission of SARS-CoV-2: Implications for Infection Prevention Precautions [Internet]. Available from: https://www.who.int/publications-detail-redirect/modes-oftransmission-of-virus-causing-covid-19-implications-for-ipcprecaution-recommendations. Accessed June 6, 2021.
  11. van Zyl-Smit RN, Richards G, Leone FT. Tobacco smoking and COVID-19 infection. Lancet Respir Med. 2020;8(7):664-5. doi: 10.1016/s2213-2600(20)30239-3.
  12. World Health Organization. GATS2 (Global Adult Tobacco Survey) Fact Sheet, India, 2016-17;2. Available from: https://www.who.int/tobacco/surveillance/survey/gats/GATS_India_2016-17_FactSheet.pdf.
  13. Zhou Z, Chen P, Peng H. Are healthy smokers really healthy? Tob Induc Dis. 2016;14:35. doi: 10.1186/s12971-016-0101-z.
  14. Vardavas CI, Nikitara K. COVID-19 and smoking: a systematic review of the evidence. Tob Induc Dis. 2020;18:20. doi: 10.18332/tid/119324.
  15. World Health Organization. Factsheet India 2018. WHO. 2018. Available from: https://apps.who.int/iris/bitstream/handle/10665/272672/wntd_2018_india_fs.pdf?sequence = 1.
  16. Saurabh S, Verma MK, Gautam V, Kumar N, Jain V, Goel AD, et al. Tobacco, alcohol use and other risk factors for developing symptomatic COVID-19 vs asymptomatic SARSCoV-2 infection: a case-control study from western Rajasthan, India. Trans R Soc Trop Med Hyg. 2021;115(7):820-31. doi: 10.1093/trstmh/traa172.
  17. WHO Global Report on Trends in Prevalence of Tobacco Use 2000-2025, Third Edition. Available from: https://www.who.int/publications-detail-redirect/who-global-report-on-trendsin-prevalence-of-tobacco-use-2000-2025-third-edition.
  18. Gupta N, Agrawal S, Ish P, Mishra S, Gaind R, Usha G, et al. Clinical and epidemiologic profile of the initial COVID-19 patients at a tertiary care centre in India. Monaldi Arch Chest Dis. 2020;90(1). doi: 10.4081/monaldi.2020.1294.
  19. Gudbjartsson DF, Helgason A, Jonsson H, Magnusson OT, Melsted P, Norddahl GL, et al. Spread of SARS-CoV-2 in the Icelandic population. N Engl J Med. 2020;382(24):2302-15. doi: 10.1056/NEJMoa2006100.
  20. Bouloukaki I, Tsoumakidou M, Vardavas CI, Mitrouska I, Koutala E, Siafakas NM, et al. Maintained smoking cessation for 6 months equilibrates the percentage of sputum CD8 + lymphocyte cells with that of nonsmokers. Mediators Inflamm. 2009;2009:812102. doi: 10.1155/2009/812102.
  21. Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis. J Infect. 2020;81(2):e16-e25. doi: 10.1016/j.jinf.2020.04.021.
  22. World Health Organization. COVID-19 Coronavirus Symptoms. WHO Publication 2020. Available from: https://www.who.int/images/default-source/health-topics/coronavirus/covid19-infographic-symptoms-final.tmb-1920v.png.
  23. Tian S, Hu N, Lou J, Chen K, Kang X, Xiang Z, et al. Characteristics of COVID-19 infection in Beijing. J Infect. 2020;80(4):401-6. doi: 10.1016/j.jinf.2020.02.018.
Journal of Oral Health and Oral Epidemiology
Volume 12, Issue 2
July 2023
Pages 77-81

Files

History

  • Receive Date: 22 December 2021
  • Revise Date: 20 September 2022
  • Accept Date: 26 December 2022

Share

How to cite

Statistics